COMMITTEE & INTEREST GROUP MEETINGS: ETHICS RESEARCH INTEREST GROUP
COMMITTEE & INTEREST GROUP MEETINGS: MEDICAL INFORMATICS INTEREST GROUP
COMMITTEE & INTEREST GROUP MEETINGS: INTEREST GROUP LEADERS’ MEETING
COMMITTEE & INTEREST GROUP MEETINGS: INFECTIOUS DISEASE MODELING INTEREST GROUP
ECONOMIC EVALUATION OF MENINGOCOCCAL SEROGROUP B CHILDHOOD VACCINATION IN ONTARIO, CANADA
PROGRAMMATIC CONSIDERATIONS IN HEALTHCARE AND THEIR IMPACT ON HEALTH OUTCOMES
COMMITTEE & INTEREST GROUP MEETINGS: MEDICAL INFORMATICS INTEREST GROUP
COMMITTEE & INTEREST GROUP MEETINGS: INTEREST GROUP LEADERS’ MEETING
COMMITTEE & INTEREST GROUP MEETINGS: INFECTIOUS DISEASE MODELING INTEREST GROUP
ECONOMIC EVALUATION OF MENINGOCOCCAL SEROGROUP B CHILDHOOD VACCINATION IN ONTARIO, CANADA
PROGRAMMATIC CONSIDERATIONS IN HEALTHCARE AND THEIR IMPACT ON HEALTH OUTCOMES
BY INVITATION ONLY. PANEL FOR COST EFFECTIVENESS IN HEALTH AND MEDICINE II MEETINGS
BY INVITATION ONLY. PANEL FOR COST EFFECTIVENESS IN HEALTH AND MEDICINE II MEETINGS, CONTINUED
F-4 HARNESSING THE POWER OF BAYESIAN STATISTICS AND PATIENT-LEVEL DATA TO PREDICT THE EFFECTIVENESS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) THERAPY IN PATIENT SUBGROUPS
BY INVITATION ONLY. PANEL FOR COST EFFECTIVENESS IN HEALTH AND MEDICINE II MEETINGS, CONTINUED
F-4 HARNESSING THE POWER OF BAYESIAN STATISTICS AND PATIENT-LEVEL DATA TO PREDICT THE EFFECTIVENESS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) THERAPY IN PATIENT SUBGROUPS
COMMITTEE & INTEREST GROUP MEETINGS: GLOBAL HEALTH INTEREST GROUP
IMPACT OF ILLICIT DRUG USE ON HEALTH UTILITY IN OPIOID DEPENDENT PATIENTS RECEIVING HIV TREATMENT
COST-EFFECTIVENESS OF RAPID HCV AND HCV & HIV TESTING IN SUBSTANCE ABUSE TREATMENT PROGRAMS
HEALTH UTILITY DURING ENGAGEMENT AND FOLLOWING DISCONTINUATION OF OPIOID SUBSTITUTION TREATMENT
N-4 TREAT, TEST, OR NEITHER? COST-EFFECTIVENESS OF CEREBROVASCULAR RESERVE IMAGING TO GUIDE TREATMENT OF CAROTID STENOSIS FOR STROKE PREVENTION
IMPACT OF ILLICIT DRUG USE ON HEALTH UTILITY IN OPIOID DEPENDENT PATIENTS RECEIVING HIV TREATMENT
COST-EFFECTIVENESS OF RAPID HCV AND HCV & HIV TESTING IN SUBSTANCE ABUSE TREATMENT PROGRAMS
HEALTH UTILITY DURING ENGAGEMENT AND FOLLOWING DISCONTINUATION OF OPIOID SUBSTITUTION TREATMENT
N-4 TREAT, TEST, OR NEITHER? COST-EFFECTIVENESS OF CEREBROVASCULAR RESERVE IMAGING TO GUIDE TREATMENT OF CAROTID STENOSIS FOR STROKE PREVENTION
UNDERSTANDING THE IMPACT OF NARRATIVES IN HEALTH NEWS: THE ROLE OF INDIVIDUAL DIFFERENCES
SMDM CORE COURSE: INTRODUCTION TO PSYCHOLOGY OF MEDICAL DECISION MAKING
J-1 RACIAL DIFFERENCES IN TREATMENT PREFERENCES AFTER USING A LOW VERSUS HIGH LITERACY PROSTATE CANCER DECISION AID
J-2 CANCER SCREENING DECISIONS: THE IMPACT OF THE AFFECT HEURISTIC IN INTERPRETATION OF TEST RISKS AND BENEFITS
K-4 SUPPORTING PATIENT VALUES: A SYSTEMATIC REVIEW OF VALUES CLARIFICATION EXERCISES
SMDM CORE COURSE: INTRODUCTION TO PSYCHOLOGY OF MEDICAL DECISION MAKING
J-1 RACIAL DIFFERENCES IN TREATMENT PREFERENCES AFTER USING A LOW VERSUS HIGH LITERACY PROSTATE CANCER DECISION AID
J-2 CANCER SCREENING DECISIONS: THE IMPACT OF THE AFFECT HEURISTIC IN INTERPRETATION OF TEST RISKS AND BENEFITS
K-4 SUPPORTING PATIENT VALUES: A SYSTEMATIC REVIEW OF VALUES CLARIFICATION EXERCISES
SMDM CORE COURSE: INTRODUCTION TO SHARED DECISION MAKING AND PATIENT DECISION AIDS
B-1 DOES BIOMARKER INFORMATION IMPACT BREAST CANCER PATIENTS' PREFERENCES FOR THERAPY?
E-1 CLINICIAN TRAINING: A CRITICAL COMPONENT FOR IMPLEMENTATION OF PATIENT DECISION AIDS
E-2 INCORPORATING SHARED DECISION MAKING AS PART OF PERFORMANCE MEASUREMENT: THE CHALLENGE OF TIMING
J-6 CHARACTERIZING SURGICAL TREATMENT DECISION INVOLVEMENT IN YOUNG WOMEN WITH BREAST CANCER
B-1 DOES BIOMARKER INFORMATION IMPACT BREAST CANCER PATIENTS' PREFERENCES FOR THERAPY?
E-1 CLINICIAN TRAINING: A CRITICAL COMPONENT FOR IMPLEMENTATION OF PATIENT DECISION AIDS
E-2 INCORPORATING SHARED DECISION MAKING AS PART OF PERFORMANCE MEASUREMENT: THE CHALLENGE OF TIMING
J-6 CHARACTERIZING SURGICAL TREATMENT DECISION INVOLVEMENT IN YOUNG WOMEN WITH BREAST CANCER
METHODOLOGICAL CHARACTERISTICS OF DECISION-ANALYTIC MODELING STUDIES FOR THE TREATMENT OF MULTIPLE MYELOMA
COST-EFFECTIVENESS ANALYSIS OF THE SEQUENTIAL APPLICATION OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
SMDM CORE COURSE: INTRODUCTION TO MEDICAL DECISION ANALYSIS (DECISION-ANALYTIC MODELING)
D-2 THE BENEFIT-HARM FRONTIER OF HPV PRIMARY SCREENING FOR CERVICAL CANCER IN GERMANY: ESTIMATES FROM A SYSTEMATIC DECISION -ANALYSIS
COST-EFFECTIVENESS ANALYSIS OF THE SEQUENTIAL APPLICATION OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
SMDM CORE COURSE: INTRODUCTION TO MEDICAL DECISION ANALYSIS (DECISION-ANALYTIC MODELING)
D-2 THE BENEFIT-HARM FRONTIER OF HPV PRIMARY SCREENING FOR CERVICAL CANCER IN GERMANY: ESTIMATES FROM A SYSTEMATIC DECISION -ANALYSIS
COMMUNITY UTILITIES ARE MUCH HIGHER THAN THOSE IN THE LITERATURE FOR A RANGE OF RADICULOPATHIES
PHYSICIANS PREFERENTIALLY SEEK INFORMATION FOR CLINICAL DECISIONS FROM COLLEAGUES VERSUS OTHER SOURCES
THE DIFFUSION OF PERCUTANEOUS BREAST BIOPSY OVER TIME
COMPLEX DISEASE MODELING: METHODS AND APPLICATIONS
PHYSICIANS PREFERENTIALLY SEEK INFORMATION FOR CLINICAL DECISIONS FROM COLLEAGUES VERSUS OTHER SOURCES
THE DIFFUSION OF PERCUTANEOUS BREAST BIOPSY OVER TIME
COMPLEX DISEASE MODELING: METHODS AND APPLICATIONS
ASSESSING THE INCREMENTAL PREDICTIVE VALUE OF MARKERS: UNDERSTANDING MODERN RECLASSIFICATION MEASURES BY A NEW GRAPHICAL DISPLAY
THE ADDED VALUE OF THE PROSTATE CANCER ANTIGEN GENE (PCA3) AND KALLIKREIN PANEL TO THE ERSPC RISK CALCULATOR FOR PROSTATE CANCER IN PRESCREENED MEN
REDUCING UNNECESSARY BIOPSIES FOR SUSPICION OF PROSTATE CANCER: SYSTEMATIC EXTENSION AND VALIDATION OF RISK CALCULATORS
H-3 COMPARING SURGICAL PERFORMANCE FOR ESOPHAGECTOMY: HOW LONG SHOULD WE FOLLOW-UP?
THE ADDED VALUE OF THE PROSTATE CANCER ANTIGEN GENE (PCA3) AND KALLIKREIN PANEL TO THE ERSPC RISK CALCULATOR FOR PROSTATE CANCER IN PRESCREENED MEN
REDUCING UNNECESSARY BIOPSIES FOR SUSPICION OF PROSTATE CANCER: SYSTEMATIC EXTENSION AND VALIDATION OF RISK CALCULATORS
H-3 COMPARING SURGICAL PERFORMANCE FOR ESOPHAGECTOMY: HOW LONG SHOULD WE FOLLOW-UP?
COMMITTEE & INTEREST GROUP MEETINGS: INTERNATIONAL ENGAGEMENT COMMITTEE
VALUATION OF DEPRESSION: DISCREPANCIES BETWEEN INDIVIDUALS WITH AND WITHOUT DEPRESSION
IDENTIFICATION OF DOMAINS FOR THE DEVELOPMENT OF A DELIVERY-SPECIFIC UTILITY MEASURE IN OBSTETRICS
SHOULD PATIENT NARRATIVES BE USED TO SUPPORT PEOPLE'S TREATMENT DECISION MAKING: AN EXPERIMENTAL STUDY ABOUT DIALYSIS OPTIONS?
DUTCH VERSION OF THE SDM-Q-9 AND SDM-Q-DOC: GOOD RELIABILITY AND MIXED RESULTS REGARDING VALIDITY
USE OF A VALUES CLARIFICATION EXERCISE ABOUT FERTILITY PRESERVATION LEADS TO MORE CLARITY ABOUT VALUES AND MORE KNOWLEDGE IN HEALTHY PARTICIPANTS
VALUATION OF DEPRESSION: DISCREPANCIES BETWEEN INDIVIDUALS WITH AND WITHOUT DEPRESSION
IDENTIFICATION OF DOMAINS FOR THE DEVELOPMENT OF A DELIVERY-SPECIFIC UTILITY MEASURE IN OBSTETRICS
SHOULD PATIENT NARRATIVES BE USED TO SUPPORT PEOPLE'S TREATMENT DECISION MAKING: AN EXPERIMENTAL STUDY ABOUT DIALYSIS OPTIONS?
DUTCH VERSION OF THE SDM-Q-9 AND SDM-Q-DOC: GOOD RELIABILITY AND MIXED RESULTS REGARDING VALIDITY
USE OF A VALUES CLARIFICATION EXERCISE ABOUT FERTILITY PRESERVATION LEADS TO MORE CLARITY ABOUT VALUES AND MORE KNOWLEDGE IN HEALTHY PARTICIPANTS